Novel Microdevices, Inc. Awarded ~$1.4M from NIH RADx® Tech to Develop a Next-generation, High Performance, Point-of-Care RT-PCR Test.
Novel Microdevices, Inc. Announces ~$1.4M Phase 1 funding from NIH RADx® Tech
![](https://biobuzz.io/wp-content/uploads/2023/08/NovelDX-Logo-1@2x-300x300.webp)
Novel Microdevices, Inc. Awarded ~$1.4M from NIH RADx® Tech to Develop a Next-generation, High Performance, Point-of-Care RT-PCR Test.
In 2019, Fulton Bank launched a new division aimed at supporting life sciences companies that many financial institutions shied away from historically—young, emerging bioscience and tech companies that offer high risk, high reward investment profiles.
CARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infections New portable battery-powered diagnostic is designed to be easy-to-use in any setting around [….]